Revisión bibliográfica de proteína C reactiva de alta sensibilidad como predictor de riesgo de enfermedad cardiovascular
| datacite.rights | http://purl.org/coar/access_right/c_16ec | spa |
| dc.contributor.advisor | Peña, Engelber | |
| dc.contributor.author | Amaya Ibarra, Aníbal Miguel | |
| dc.contributor.author | Tatis Mendoza, Martin Fernando | |
| dc.date.accessioned | 2024-03-08T22:55:52Z | |
| dc.date.available | 2024-03-08T22:55:52Z | |
| dc.date.issued | 2015 | |
| dc.description.abstract | Las enfermedades cardiovasculares son un auténtico problema de salud pública en nuestro entorno debido a su alta prevalencia y mortalidad y a su elevada hospitalización asociada. Pese a los importantes e innegables avances terapéuticos en las últimas décadas, la condicion esencial del riesgo y la evaluación pronostica de la insuficiencia cardiaca sigue siendo difícil, máxime si nos basamos en datos clínicos. Últimamente mediante investigaciones se ha observado que la inflamación es un mecanismo clave de la aterogénesis y de la progresión rápida de la enfermedad arterial coronaria. La inflamación es una respuesta del huésped a una gran variedad de lesiones tisulares. Cuando el estímulo inflamatorio es persistente o se repite continuamente se producirá una inflamación crónica, que puede llegar a destruir el tejido y/o producir la pérdida de la funcionalidad del órgano afectado. En la aterosclerosis, como en otras patologías que implican una respuesta inflamatoria, las citosinas aumentarán las concentraciones sanguíneas de reactantes de fase aguda (marcadores de inflamación activa) como el fibrinógeno o la proteína C reactiva. Recientemente se ha observado que estas _proteínas están más elevadas en aquellos individuos con eventos cardiovasculares durante los siguientes años, ya sea personas sanas o pacientes con cardiopatía isquémica. | spa |
| dc.format.mimetype | spa | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12442/14313 | |
| dc.language.iso | spa | spa |
| dc.publisher | Ediciones Universidad Simón Bolívar | spa |
| dc.publisher | Facultad de Ciencias de la Salud | spa |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | eng |
| dc.rights.accessrights | info:eu-repo/semantics/restrictedAccess | spa |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
| dc.subject | Enfermedades cardiovasculares | spa |
| dc.subject | Salud pública | spa |
| dc.subject | Proteína C reactiva | spa |
| dc.title | Revisión bibliográfica de proteína C reactiva de alta sensibilidad como predictor de riesgo de enfermedad cardiovascular | spa |
| dc.type.driver | info:eu-repo/semantics/bachelorThesis | spa |
| dc.type.spa | Trabajo de grado - pregrado | spa |
| dcterms.references | Atillett WS, Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of the pneumococcus. J Exp Med. 1930; 52:561-71. | eng |
| dcterms.references | Macleod C, Avery O. The occurrence during acute infections of a protein not normally present in the blood. ll. Isolation and properties of the reactive protein. J Exp Med. 1941; 73:183-90. | eng |
| dcterms.references | Pepys MB, Baltz ML. Acute phase proteins with special reference to C-reactive protein and related proteins (pentraxinas) and serum amyloid a pro-tein. Advimmunol. 1983; 34:141-212 | eng |
| dcterms.references | Casas JT, Shah T, Hingorani AD, Danesh J, Pepys M B. C-reactive protein and coronary heart disease: a critical review. J Int Med. 2008; 264:295-314. | eng |
| dcterms.references | Thompson D, Pepys MB, Wood SP. The physiological structure of human Creactive protein and its complex with phosphocholine.Structure. 1999; 7:169-77. | eng |
| dcterms.references | Calabro P, Chang DW, Willerson JT, Yeh ET. Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. J Am Coll Cardiol. 2005; 46: 1 112-3. | eng |
| dcterms.references | Rocha VZ, Libby P, Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol. 2009; 6:399409. | eng |
| dcterms.references | Calabro P, Willerson JT, Yeh ET. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation. 2003; 108:1930-2. | eng |
| dcterms.references | Yasojima K, Schwab C, McGee EG, McGee PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol. 2001; 158: 1039-51. | eng |
| dcterms.references | Hutchinson WL, Noble GE, Hawkins PN, Pepys MB. The pentraxinas, Creactive protein and serum amyloid P component, are cleared and catabolized by hepatocytes in vivo. J Clin Invest. 1994; 94:1390-6. | eng |
| dcterms.references | Ledue TB, Rifai N. Preanalytic and analytic sources of variations in C-reactive protein measurement: implications for cardiovascular disease risk assessment. Clin Chem. 2003; 49:1258-71 | eng |
| dcterms.references | Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, et al. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association.Circulation. 2003; 107•.499-511. | eng |
| dcterms.references | Roberts WL, Moulton L, Law TC, Farrow G, Cooper-Anderson M, Savory J, Rifai N. Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Clin Chem. 2001; 47:41825. | eng |
| dcterms.references | Ridker PM. C-reactive protein: eighty years from discovery to emergence as a major risk marker for cardiovascular disease. Clin Chem. 2009; 55:209-15. | eng |
| dcterms.references | Myers GL, Christenson RH, Cushman M, Ballantyne CM, Cooper GR, Pfeiffer CM, et al. National Academy of Clinical Bio-chemistry Laboratory Medicine. Practice guidelines: Emerging biomarkers. | eng |
| dcterms.references | The Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant metaanalysis. Lancet. 2010; 375:13240. | eng |
| dcterms.references | Arena R, Arrowroot JA, Fei DY, Helm S, Kraft KA. The relationship between Creactive protein and other cardiovascular risk factors in men and women CardiopulmRehabil. 2006; 26•.323-27. | eng |
| dcterms.references | Devaraj S, Singh IJ, Jialal l. The evolving role of C-reactive protein in atherothrombosis.CIin Chem. 2009; 55:229-38. | eng |
| dcterms.references | Jialal l, Verma S, Devaraj S. Inhibition of endothelial nitric oxide synthase by Creactive protein: clinical relevance. Clin Chem. 2009; 55:206-8. | eng |
| dcterms.references | Bisoendial RJ, Boekholdt SM, Vergeer M, Stroes ESG, Kastelein JJP. Creactive protein is a mediator of cardiovascular disease. Eur. Heart J. 2010; 31.•2087-95. Anand SS, Yusuf S. C-reactive protein is a bystander of cardiovascular disease. Eur Heart J. 2010; 31:2092-7. | eng |
| dcterms.references | Ridker P M. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk moving an inflammatory hypothesis toward consensus J Am CollCardiol. 2007; 49:2129-38. | eng |
| dcterms.references | Kushner l, Brooder ML, Karp D. Control of the acute phase response. Serum C-reactive protein kinetics after acute myocardial infarction. J Clin Invest. 1978; 61:235-42. | eng |
| dcterms.references | Beer FC, Hind CRK, Fox KM, Allan R, Maseri A, Pepys MB. Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction.Br Heart J. 1982; 47:239-43. | eng |
| dcterms.references | Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol. 1990; 65:168-72. | eng |
| dcterms.references | Haverkate F, Thompson SG, Pyke SDM, Gallimore JR, Pepys MB, for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Production of C-reactive protein and risk of coronary events in stable and unstable patients. Lancet. 1997; 349:462-6. | eng |
| dcterms.references | Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW, for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Hemostatic factors and the risk of myocardial infarction or sud-den death in patients with angina pecto-ris.N Engl J Med. 1995; 332:635-41. | eng |
| dcterms.references | Luis C. L. Correial e J. Pericles Esteves2 Escola Bahiana de Medicinal, Universidad e Federal da Bahia2, Salvador, BA — Brasil | spa |
| dcterms.references | Mario Flores, MD, MS, I ; Simon Barquera, MD, MS, PhD; Citlalli Carriån, MC, M en C,l ; Rosalba Rojas, M en C, PhD; Salvador Villalpando, MD, PhD; Gustavo Olaiz-Fernåndez, MC, MSPII; Clicerio Gonzålez-Villalpando, MC, M Esp,DeBeer FC, Hind CR, Fox KM, Allan RM, Maseri A, Pepys MB: Measurement of serum C— reactive proteinconcentration in myocardialischaemia and infarction. Br Heart J 1982; 47: 239-43. | eng |
| dcterms.references | Griselli M, Herbert J, Hutchinsin WL, Laylor KM, Sohail M, Krausz L, et al: C— reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med 1999; 190: 1733—40. | eng |
| dcterms.references | Ridker PM: Clinical application of C—reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363—9. | eng |
| dcterms.references | Ridker PM, Rifai N, Pfeiffer MA, Sacks FM, Moyela, Goldman S, et al: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998; 98: 8439-44. | eng |
| dcterms.references | Jialal l, Devaraj S, and Venugopal SK: C—reactive protein: risk marker or mediator in atherothrombosis? Hypertension 2004; 44: 6. | eng |
| dcterms.references | Zwaka TP, Hombach V, Torzewski J: C—reactive protein—mediated low—density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001; 103: 1194—7. | eng |
| dcterms.references | Gershov D, Kim S, Brot N, and Elkon KB: C—reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an anti-inflammatory innate immune response: implication for systemic autoimmunity. J Exp Med 2000; 192: 1353—63. | eng |
| dcterms.references | Pepys MB, Rowe IF, and Baltz ML: C—reactive protein: binding, to lipids and lipoproteins. Int Rev ExpPathol 1985; 27: 83—111. Vigushin DM, Pepys MB, pHawkins PN: Metabolic and scintigraphic studies of radioiodinated human C—reactive protein in health and disease. J Clin Invest 1993; 91: 1351-7. | eng |
| dcterms.references | US Department of Health and Human Services. Food and Drug Administration. Review criteria for assessment of C-reactive protein (CRP), high sensitivity Creactive protein (hsCRP) and cardiac C-reactive protein (cCRP) Assays. Document issued on: September 22, 2005. | eng |
| dcterms.references | Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice. A statement for health care professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107•.499-511. | eng |
| dcterms.references | Yamaii K, Wang Y, Liu Y, Abeyama K, Hashiguchi T, Uchimura T, et al: Activated protein C, a natural anticoagulant protein, has antioxidant properties and inhibits lipidperoxidation and advanced glycation end products formation. Thromb Res 2005; | eng |
| dcterms.references | Van H, Rosendaal FR. High levels of fibrinogen are associated with the risk of deep venous thrombosis mainly in the elderly. J Thromb Headmost. 2003; 1 (12): 2677-8. | eng |
| dcterms.references | Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklaus BJ, SuttonTyrrell K, et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation. 2003; 108: 2317-22. | eng |
| oaire.version | info:eu-repo/semantics/acceptedVersion | spa |
| sb.programa | Medicina | spa |
| sb.sede | Sede Barranquilla | spa |
Archivos
Bloque original
1 - 1 de 1
No hay miniatura disponible
- Nombre:
- PDF.pdf
- Tamaño:
- 11.58 MB
- Formato:
- Adobe Portable Document Format